GGrantIndex
Sort

39,280 grants matching leukemia

Complexity, Cooperation and Community in Cancer

$2,087,357
John Lowengrub · University Of California-Irvine · U54 · FY2021 · CA

Genomics Of Acute Myeloid Leukemia.

$2,084,756
Timothy J Ley · Washington University · P01 · FY2019 · CA

Topology of Cancer Evolution and Heterogeneity

$2,081,527
Raul Rabadan · Columbia University Health Sciences · U54 · FY2016 · CA

Off-the-Shelf Immune Effector Cells for Hematological Malignancies

$2,080,518
John E Wagner · University Of Minnesota · P01 · FY2025 · CA

Innate Immunity: Elucidation and Modulation for Cancer Therapy

$2,080,062
Michael A Caligiuri · Ohio State University · P01 · FY2010 · CA

Biology & Transplantation of the Human Stem Cell

$2,080,053
Philip McGlave · University Of Minnesota · P01 · FY2008 · CA

Detection, prevention and treatment of acute myeloid leukemia (AML) relapse.

$2,079,438
Christopher Hourigan · National Heart, Lung, And Blood Institute · ZIA · FY2018 · HL

Targeted Sphingolipid Metabolism for Treatment of AML

$2,077,502
Thomas P Loughran · University Of Virginia · P01 · FY2015 · CA

Engineered bone marrow niche to reconstitute T cell immunity

$2,076,253
David T Scadden · Harvard University · U54 · FY2019 · CA

Hematopoietic Stem Cells for Transplantation

$2,075,973
Saul J Sharkis · Johns Hopkins University · P01 · FY2012 · CA

Eosinophils and Eosinophil Activation in the Pathogenesis of Human Disease

$2,075,838
Amy Klion · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI

Hematopoietic Stem Cells for Transplantation

$2,075,614
Saul J Sharkis · Johns Hopkins University · P01 · FY2011 · CA

Preventing Relapse After Non-myeloablative Stem Cell Transplantation: The Final Challenge

$2,074,913
Brenda Marie Sandmaier · Fred Hutchinson Cancer Center · P01 · FY2025 · CA

Preventing Relapse After Non-myeloablative Stem Cell Transplantation: The Final Challenge

$2,074,913
Brenda Marie Sandmaier · Fred Hutchinson Cancer Center · P01 · FY2023 · CA

NK cells, their receptors and unrelated donor transplant

$2,074,355
Jeffrey S Miller · University Of Minnesota · P01 · FY2014 · CA

Biology & Transplantation of the Human Stem Cell

$2,072,348
Philip McGlave · University Of Minnesota · P01 · FY2006 · CA

Preventing Relapse After Non-myeloablative Stem Cell Transplantation: The Final Challenge

$2,071,892
Brenda Marie Sandmaier · Fred Hutchinson Cancer Center · P01 · FY2022 · CA

Growth Factor Imaging and Photoimmunotherapy

$2,071,751
Peter L. Choyke · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA

Novel Therapeutic Strategies in Human Myeloid Leukemias

$2,071,388
Dana-Farber Cancer Institute · P01 · FY2003 · CA

Acquisition of a High-Field Dual Source FTICR-MS for Pharmaceutical Research

$2,070,000
Lingjun Li · University Of Wisconsin-Madison · S10 · FY2011 · RR

Translational Multimodality " Antibody" Therapy

$2,069,586
University Of California Davis · P01 · FY2004 · CA

Extending Chimeric Antigen (CAR) T cell therapy to thoracic cancers

$2,069,565
Steven Mark Albelda · University Of Pennsylvania · P01 · FY2019 · CA

Administrative Core A

$2,069,128
Benjamin Levine Ebert · Dana-Farber Cancer Inst · P50 · FY2020 · CA

Biology & Transplantation of the Human Stem Cell

$2,065,942
Philip McGlave · University Of Minnesota · P01 · FY2007 · CA

BIOLOGY AND GENETICS OF MARROW ALLOGRAFTS FOR LEUKEMIA

$2,065,351
Sloan-Kettering Institute For Cancer Res · P01 · FY2000 · CA